PAVmed Partners with Duke University to Innovate Esophageal Dysplasia Diagnosis Technology

PAVmed Partners with Duke University to Advance Esophageal Dysplasia Diagnosis

PAVmed Inc. has recently strengthened its position in the medical technology landscape by signing a non-binding letter of intent with Duke University to license an innovative endoscopic imaging technology. This groundbreaking technology, developed by Duke biomedical engineer Dr. Adam Wax, leverages angle-resolved low coherence interferometry (a/LCI) in conjunction with optical coherence tomography (OCT). The collaboration aims to enhance the diagnosis and treatment of esophageal dysplasia, a condition that poses significant risks, including the potential development of esophageal cancer. Traditional biopsy methods often suffer from sampling errors and extend the time required for diagnosis, sometimes taking weeks, which can delay critical treatment decisions.

The integration of a/LCI with OCT provides a substantial advancement over conventional techniques, allowing for real-time detection of esophageal dysplasia during endoscopic procedures. This immediate feedback enables clinicians to make timely treatment decisions, potentially transforming the standard of care for patients suffering from Barrett's esophagus. Dr. Nicholas Shaheen, a leading expert in esophageal precancer, underscores the urgency of this development, noting that the new technology could significantly enhance patient outcomes while streamlining healthcare resources. As non-endoscopic biomarker testing becomes more prevalent, it is expected that the number of patients referred for confirmatory endoscopy and treatment will rise, further increasing the demand for such innovative diagnostic tools.

The partnership between PAVmed and Duke University exemplifies a shared commitment to advancing medical technology solutions that improve diagnostic and therapeutic processes. Once the a/LCI + OCT technology is fully developed and approved, it is anticipated to serve as a vital resource for clinicians managing Barrett's esophagus, thereby playing a crucial role in the fight against esophageal cancer. This collaboration not only positions PAVmed at the forefront of medical innovation but also highlights its dedication to developing solutions that directly address significant healthcare challenges.

In addition to this partnership, PAVmed continues to pursue advancements across its diverse portfolio of medical technologies. The company remains focused on integrating innovative solutions that address unmet clinical needs, thereby enhancing patient care and outcomes. As the healthcare landscape evolves, PAVmed's initiatives reflect a proactive approach to improving diagnostic accuracy and treatment efficacy in various medical fields.